Results: AVO

Search articles by EPIC code
EPIC AVO
views

Advanced Oncotherapy – First LIGHT System Delayed: Oopsadaisie……Still a Sell

Well surprise, surprise! AIM-listed Advanced Oncotherapy (AVO) has announced that the first fully operational LIGHT system has been delayed from the end of this year to the end of Q1 next year. I noted HERE that the delay announced this morning was pretty well baked in. Given that we have moved from “could slip into Q1 2022” to “around the end of Q1 2022” in the space of less than two and a half months, it seems to me that further slippage is highly likely. Indeed, despite this morning’s announcement, one wonders whether any progress has been made at all since the announcement of diabolical interims at the end of September. So there will be at least another quarter sans revenue……what about the cash?

EPIC AVO
views

Advanced Oncotherapy – ‘Fesses Up at No-One-Is-Watching O’clock, BUT It Is Still Wrong!

Back on August 17th I pointed out that according to AIM-listed Advanced Oncotherapy’s FY20 Annual Report, all the warrants exercisable at 25p issued back in July 2017 should have expired. Yet the night before, after-hours, the company had announced the exercise of 500,000 of those warrants. Last night the company slipped out an explanation at 6.14pm in its Result of GM announcement.

EPIC AVO
views

BREAKING: Red Flags at Night: Advanced Oncotherapy Warrant Conversion is this an illegitimate free £75,000 for someone?

Here is an odd thing: last night, after hours at 4.48pm, AIM-listed Advanced Oncotherapy (AVO) announced that someone had issued an exercise notice in respect of 500,000 warrants issued back in July 2017 to subscribe for ordinary shares at 25p. Application to admit the shares has been made and admission is expected on or around August 20th. So what, you might ask. And that brings me to Advanced’s Annual Report for FY20.

EPIC AVO
views

Advanced Oncotherapy - £40m Fundraise, Biggest to Date. So it is a Buy? Er…..

AIM-listed protons beams for cancer outfit Advanced Oncotherapy (AVO) announced a proposed £40 million fundraise yesterday – the largest to date – at 40p per share, a 17% premium to its average closing price over the past month, and a 13% premium to the previous close. I have to hand it to the company, that’s a great effort. But does it make the shares a buy?

EPIC AVO
views

Advanced Oncotherapy Rattles the Tin Once Again – This time for a £6m fundraise

When I last wrote about AIM-listed Advanced Oncotherapy, at the end of October last year, it had just announced a placing at 30p per share to raise £7.7 million and my back-of-a-fag-packet suggested that despite the new money, it was placing ahoy. Well, yesterday that placing duly arrived with £6 million raised at a rather more impressive 40p. So will this be the last time the company passes round the hat? 

Page 1 of 24 (237 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|